The Roivant Discovery fully integrated approach to drug discovery and development enables us to design small molecule therapeutic candidates for challenging targets in areas of unmet medical need.
From Chip to Clinic
Roivant’s proprietary computational physics-driven platform, in-house research laboratories and clinical development expertise allow us to more accurately design, validate and develop therapeutics to address protein targets that have historically been difficult to drug.
Design Loop: Atomistic Shifts, Massive Results
Roivant Discovery is pioneering a physics-driven approach to drug design in which our quantum physics-based molecular simulations go beyond binding to augment ideation and evaluation within the design cycle. We virtually screen billions putative of small molecule therapeutic candidates and simulate thousands of the top candidates using rigorous free energy approaches, ultimately leading to the design of better drugs, atom-by-atom. Our approach delivers insights into the properties of each drug candidate and enables us to evaluate novel candidates against the desired biological outcome, testing the most promising molecules in our laboratories.
Connecting the Dots
At Roivant Discovery our platform method developers work with our chemists, biologists, biophysicists, modelers, software engineers, and parallel computing experts as a unified team every day to identify critical drug discovery bottlenecks, formulate purpose-built algorithms, and deploy solutions. Our high-performance computing cluster further strengthens the team’s ability to perform rigorous free energy-based simulations at scale in response to data uncovered in new iterations of the molecular design loop.